Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Available Antibiotic Therapy for the Treatment of Adults With Bacteremia Due to Staphylococcus Aureus

NCT05184764 is registered in ClinicalTrials.gov with Armata Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05184764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05184764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Available Antibiotic Therapy for the Treatment of Adults With Bacteremia Due to Staphylococcus Aureus
Lead sponsor
Armata Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
April 26, 2022
Completion date
January 14, 2025
Enrollment
56 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

bacteremia, bacteremia due to staphylococcus aureus, bacteremia staph, staphylococcus aureus, staphylococcus aureus bacteremia